Preliminary Clinical Study Using a Novel Wound Dressing Composed of Hyaluronic Acid and Collagen Containing EGF

Yu, Akane; Kumazawa, Kenichi; Miyoshi, Hiroshi; Kuroyanagi, Misato; Yoshitake, Toshihiro; Uchinuma, Eiju; Suzuki, Ryusuke; Yoshimitsu, Kengo

doi:10.4236/ojrm.2015.41002

Cited by 11 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High molecular weight HA is useful to create an excellent wound healing environment, while low molecular weight HA is useful to promote angiogenesis. Both side of spongy sheet was irradiated with an ultraviolet lamp in order to induce intermolecular cross-linking among Col molecules [24][25][26]. This wound dressing (5 cm × 8 cm) contains EGF at a concentration of 2.0 μg/cm 2 .…”

Section: Volume 3 • Issue 1 • 1000137 Dermatol Case Rep An Open Accementioning

confidence: 99%

“…This CDS can release various types of growth factors even after cryopreserving and thawing process. As the second research strategy, we developed a functional wound dressing that is composed of a spongy sheet of HA and Col containing epidermal growth factor (EGF) [24][25][26]. EGF is able to facilitate both keratinocyte and fibroblast proliferation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advanced Treatment of Burns and Skin Ulcers Using Tissue-Engineered Products

Kuroyanagi¹,

Yoshimitsu²

2018

Dermatol Case Rep

Self Cite

View full text Add to dashboard Cite

Three types of tissue-engineered products have been introduced in this review. The first product is an allogeneic cultured dermal substitute. This product is manufactured by incorporating allogeneic fibroblasts into a spongy sheet of hyaluronic acid and collagen. Allogeneic fibroblasts are rejected gradually in immune system. However, they are able to release some growth factors that are essential for wound healing. Hyaluronic acid and collagen also have a potential to promote wound healing. The clinical study demonstrated that this cultured dermal substitute is useful for the treatment of burns and skin ulcers. The second product is a functional wound dressing. This product is manufactured by freeze-drying an aqueous solution of hyaluronic acid, collagen, and epidermal growth factor. Epidermal growth factor has a potential to promote wound healing by enhancing both keratinocyte and fibroblast proliferation, and also by stimulating fibroblasts to synthesize vascular endothelial growth factor and hepatocyte growth factor that are essential for angiogenesis. The clinical study demonstrated that this wound dressing is useful for the treatment of burns and skin ulcers. The third product is a skin care product. This product is manufactured by freeze-drying an aqueous solution of hyaluronic acid, collagen, epidermal growth factor, and other ingredients for skin care. The experiment using a culture system demonstrated that this skin care product stimulates fibroblast to synthesize an increased amount of vascular endothelial growth factor and hepatocyte growth factor. This skin care product is aimed to use for post-treatment of chemical peeling and laser therapy used in aesthetic dermatology.

show abstract

Section: Volume 3 • Issue 1 • 1000137 Dermatol Case Rep An Open Accementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Advanced Treatment of Burns and Skin Ulcers Using Tissue-Engineered Products

Kuroyanagi¹,

Yoshimitsu²

2018

Dermatol Case Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Considering these efficacies of EGF and VC, we developed a functional wound dressing composed of HA and Col containing EGF [11]- [14]. This EGF-incorporating wound dressing showed the potential to facilitate granulating tissue formation associated with angiogenesis, and to accelerate epithelialization in rats and diabetic mice.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Epidermal Growth Factor-Incorporating Skin Care Product in Culture Experiment Using Human Fibroblasts

Yamamoto¹,

Ohno²,

Yoshimitsu³

2016

OJRM

Self Cite

View full text Add to dashboard Cite

This study aimed to investigate the potential of a skin care product composed of hyaluronic acid (HA) and collagen (Col) sponge containing epidermal growth factor (EGF), vitamin C derivative (VC), glucosylceramide (GC), poly(γ-glutamic acid) (PGA), and argentine (Arg). High-molecular weight HA aqueous solution, hydrolyzed low-molecular weight HA aqueous solution, and heat-denatured Col aqueous solution were mixed, into which each aqueous solution containing EGF, VC, GC, PGA, or Arg were added, followed by freeze-drying to obtain a spongy EGF-incorporating skin care product (EGF-skin care product). In order to evaluate the first efficacy of EGF, fibroblast proliferation was assessed after 6 days of cultivation in the conditioned medium prepared by dissolving EGFskin care product in a conventional culture medium. The fibroblast densities increased more effectively in conditioned medium with EGF than in control medium without EGF. In order to evaluate the second efficacy of EGF, the amount of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) produced by fibroblasts were assessed in a wound surface model. A fibroblast-incorporating Col gel sheet (cultured dermal substitute: CDS) was elevated to the airmedium interface, onto which a spongy sheet of EGF-skin care product was placed and cultured for 7 days. The condition covered with or without EGF-skin care product is divided into (+) EGF or (−) EGF, respectively. Fibroblasts in the CDS released 3.7 times more VEGF and 25 times more HGF in (+) EGF compared with (−) EGF. In another experiment, an aqueous solution of EGF-skin care product was added onto CDS and cultured for 7 days. Aqueous solutions were prepared and stored at 4˚C or 37˚C for a different period of 1 day, 2 weeks, and 4 weeks, respectively. Fibroblasts in CDS under different condition released similar amount of VEGF and HGF. This result indicated that the efficacy of EGF was maintained even after preservation at 37˚C for 4 weeks. These findings suggest * Corresponding author. A. Yamamoto et al. 45 that EGF-skin care product can be used on damaged skin surface by placing its spongy sheet or its solution.

show abstract

“…This treatment using EGF-wound dressing was applied repeatedly at an interval of 3 to 5 days for a period of 6 weeks, or longer if necessary. Excellent and good results were assessed in 93.7% of the all cases in total clinical evaluation [19].…”

Section: Egf-incorporating-wound Dressingmentioning

confidence: 99%

“…This freeze-dried wound dressing is very practical for the treatment of burn injury. The clinical study showed that EGF-incorporating wound dressing is a practical product [19]. Based on the design concept of EGFincorporating wound dressing, we developed EGF-incorporating anti-adhesive product [20].…”

Section: Introductionmentioning

confidence: 99%

Preliminary Clinical Study Using a Novel Wound Dressing Composed of Hyaluronic Acid and Collagen Containing EGF

Cited by 11 publications

References 11 publications

Advanced Treatment of Burns and Skin Ulcers Using Tissue-Engineered Products

Advanced Treatment of Burns and Skin Ulcers Using Tissue-Engineered Products

Evaluation of Epidermal Growth Factor-Incorporating Skin Care Product in Culture Experiment Using Human Fibroblasts

Design Concept of Tissue-Engineered Products for Use in Emergency and Critical Care Medicine

Contact Info

Product

Resources

About